Bausch Health Companies (BHC) Competitors

Bausch Health Companies (NYSE:BHC) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, community ranking, institutional ownership, earnings, valuation and profitability.

Does the media refer more to BHC or ASND?

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Bausch Health Companies. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 7 mentions for Bausch Health Companies. Bausch Health Companies' average media sentiment score of 0.63 beat Ascendis Pharma A/S's score of 0.58 indicating that Bausch Health Companies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Companies	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is BHC or ASND more profitable?

Bausch Health Companies has a net margin of -0.48% compared to Ascendis Pharma A/S's net margin of -104.54%. Ascendis Pharma A/S's return on equity of 0.00% beat Bausch Health Companies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Companies	-0.48%	-577.82%	5.24%
Ascendis Pharma A/S	-104.54%	N/A	-39.23%

Which has better valuation & earnings, BHC or ASND?

Bausch Health Companies has higher revenue and earnings than Ascendis Pharma A/S. Bausch Health Companies is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Companies	$9.63B	0.28	-$46M	-$0.12	-60.54
Ascendis Pharma A/S	$363.64M	28.04	-$409.12M	-$7.10	-23.66

Which has more risk & volatility, BHC or ASND?

Bausch Health Companies has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.

Do analysts recommend BHC or ASND?

Bausch Health Companies presently has a consensus target price of $7.42, suggesting a potential upside of 2.09%. Ascendis Pharma A/S has a consensus target price of $204.64, suggesting a potential upside of 21.82%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Bausch Health Companies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Companies	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93

Does the MarketBeat Community favor BHC or ASND?

Ascendis Pharma A/S received 88 more outperform votes than Bausch Health Companies when rated by MarketBeat users. Likewise, 66.82% of users gave Ascendis Pharma A/S an outperform vote while only 61.26% of users gave Bausch Health Companies an outperform vote.

Company	Underperform	Outperform
Bausch Health Companies	Outperform Votes 359 61.26%	Underperform Votes 227 38.74%
Ascendis Pharma A/S	Outperform Votes 447 66.82%	Underperform Votes 222 33.18%

Do institutionals & insiders hold more shares of BHC or ASND?

78.7% of Bausch Health Companies shares are owned by institutional investors. 8.1% of Bausch Health Companies shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Ascendis Pharma A/S beats Bausch Health Companies on 11 of the 18 factors compared between the two stocks.